PIQRAY® (alpelisib) FDA Approved for the Treatment of Patients with a PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer , Available Exclusively at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy for PIQRAY, indicated with fulvestrant for adults with PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer.
VIJOICE® (alpelisib) FDA Approved for the Treatment of Patients with PIK3CA-Related Overgrowth Spectrum (PROS), Available Exclusively at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy for VIJOICE, indicated for adults and children age 2 and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum.